18,577 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Purchased by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 18,577 shares of the medical research company's stock, valued at approximately $3,429,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after buying an additional 3,738,018 shares in the last quarter. Norges Bank acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $98,886,000. Raymond James Financial Inc. acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $42,776,000. Cooke & Bieler LP increased its stake in Charles River Laboratories International by 42.1% during the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company's stock worth $78,781,000 after purchasing an additional 126,372 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after purchasing an additional 85,759 shares during the period. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Up 1.1 %

NYSE:CRL traded up $1.59 during midday trading on Wednesday, hitting $147.58. 415,217 shares of the company were exchanged, compared to its average volume of 1,159,005. Charles River Laboratories International, Inc. has a fifty-two week low of $142.76 and a fifty-two week high of $264.70. The company has a market capitalization of $7.55 billion, a PE ratio of 983.85, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $163.95 and a 200 day simple moving average of $181.92.

Remove Ads

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business's revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.46 earnings per share. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on CRL shares. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Morgan Stanley reduced their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price for the company in a research note on Monday, March 3rd. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their price target for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, Barclays decreased their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $189.77.

Insider Activity

In related news, CEO James C. Foster purchased 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).